Cansino Biologics became the first vaccine maker to list on the Hong Kong Stock Exchange this week, thanks to listing reforms which permit pre-revenue biotech companies and tech companies to raise capital in the city. Photo:

Ebola vaccine maker CanSino Biologics has a plan to take its life-saving treatments well beyond China’s domestic market

  • CanSino Biologics jumped 59 per cent in debut trading in Hong Kong on Thursday, reflecting the best first day trading gain in the city since 2017
  • Steve Chao, chief operating officer, says the company has 15 vaccines under development
Topic |   IPO

TOP PICKS

Cansino Biologics became the first vaccine maker to list on the Hong Kong Stock Exchange this week, thanks to listing reforms which permit pre-revenue biotech companies and tech companies to raise capital in the city. Photo:
READ FULL ARTICLE